TransCode and Quantum Leap seek FDA approval for Phase IIa TTX-MC138 trial

A partnership comprising TransCode Therapeutics and Quantum Leap Healthcare Collaborative has submitted an investigational ...

Biomednewsbreaks Transcode Therapeutics, Inc. (NASDAQ: RNAZ) Submits IND Amendment For Planned Phase 2A Trial Of TTX-MC138 In Colorectal Cancer

Submits IND Amendment For Planned Phase 2A Trial Of TTX-MC138 In Colorectal Cancer. TransCode Therapeutics (NASDAQ: RNAZ) announced the submission of an Investigational New Drug (“IND”) application ...

TransCode Therapeutics, Inc.: TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138

TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (TransCode), a clinical stage company pioneering immuno-oncology and RNA therapeutics ...
Le Lézard

Edgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026

Edgewise Therapeutics, Inc., , a leading muscle disease biopharmaceutical company, today announced that Behrad Derakhshan, Ph.D., Chief Operating Officer, will present at the Guggenheim Emerging ...
Le Lézard

PTC Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, Feb. 19, 2026

PTC Therapeutics, Inc. announced today that the company will host a webcast conference call to report its fourth quarter and full year 2025 financial results and provide an update on the company's ...

TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138

TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (TransCode), a clinical stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers, in collaboration ...